The quest for improving live birth rate in IVF is never ending and one important component to achieve this goal is embryo selection. This has led to the development of PGT-A. The traditional method of PGT-A offered at Flinders Fertility and most other clinics involves biopsying the outer part of an embryo (the trophectoderm) at blastocyst stage and then performing an assessment through DNA amplification to identify the number of chromosomes. Embryos with normal chromosome numbers are then selected for transfer.
Studies show that PGT-A reduces the time to pregnancy and reduces the risk of miscarriage. However, there are several limitations to the technology such as the risk of potential loss of embryos during biopsy, and the presence of mosaicism (providing inconclusive results). Studies so far show that PGT-A is not associated with an increase in live birth rates or cumulative pregnancy rates, and in fact there may be a reduced cumulative pregnancy rate. The search for best method to select the genetically normal embryo which is robust and results in a live and healthy birth continues.
One such method still undergoing research and currently being offered at some clinics is non-invasive genetic testing of embryos. This method relies on extracting DNA from the culture media in which the embryo has developed. Currently the accuracy of this method is being tested by comparing it with the results of standard PGT-A (ie trophectoderm biopsy), which in itself is not perfect at this stage as it limited by mosaicism. The current rate of concordance between non-invasive and conventional PGT-A varies between 50-70%, which means that the results are far less reliable that conventional PGT-A technology. This is insufficient for Flinders Fertility to recommend this technology at the present time.
There are other limitations of non-invasive PGT-A. Unlike standard PGT-A, only embryos created using ICSI are suitable for assessment and these are known to have inferior outcomes compared to standard IVF. Currently ICSI is recommended only if there is risk of failed fertilisation with standard insemination, or where there is severe male factor infertility.
Other challenges for non-invasive PGT-A include:
Therefore, several technical challenges need yet to be addressed before accepting non-invasive PGT-A as a reliable source of identifying chromosomally normal (euploid) embryos. Well-designed studies are required to determine how accurately cell free DNA represents the genetic constitution of the whole embryo and to evaluate the clinical efficacy of these methods on pregnancy outcomes. Flinders Fertility in conjunction with PerkinElmer is currently involved in one such study. Until we have robust evidence for the efficacy and safety of non-invasive PGT-A, standard trophectoderm biopsy for PGT-A remains the optimal method for obtaining embryo derived DNA for PGT-A.
Coronavirus disease (COVID-19) is a respiratory illness caused by a new virus.
If you have a fever, cough, sore throat, shortness of breath or any other respiratory symptoms or if you have travelled overseas in the past 14 days, please postpone your appointment for 2 weeks. Please stay home and if you have any relevant symptoms, contact your healthcare provider by phone for guidance about clinical management before you visit us.
If you are concerned that you have contracted COVID-19 please call the Coronavirus Health Line 1800 020 080 or the Healthdirect Hotline 1800 022 222.